CMC Biologics has entered into an agreement with Symphogen for process development and cGMP manufacture of an undisclosed polyclonal antibody product candidate from Symphogen’s development pipeline. Terms of the agreement were not disclosed.     “We are pleased to establish such a partnership with Symphogen and are excited to be involved in this unique field of recombinant polyclonal antibody technology,” said Mads Laustsen, chief executive officer of CMC Biologics....